EU Report Raises Questions About Nicotine Pouches
A growing debate around nicotine pouches is unfolding in Europe. At the centre is a report from the European Commission’s Joint Research Centre (JRC), which calls for caution and highlights uncertainties regarding the long-term health effects of these products.
Key Takeaways
- A new report by the European Commission argues that the evidence for nicotine pouches is currently limited.
- Haypp’s Senior Director of External Affairs, Dr Marina Murphy, argues against the report’s findings.
- Studies point to the fact that nicotine pouches appear to be closer to nicotine replacement therapies (NRTs) than traditional tobacco products.
- Nicotine pouches do not contain tobacco and do not produce combustion, unlike cigarettes.
New Report Cautions Against Nicotine Pouches
The report, "Health outcomes associated with the use of e-cigarettes, heated tobacco products, and nicotine pouches", concludes that the evidence base for nicotine pouches remains limited and that its role in smoking cessation is unclear.
At the same time, it recommends a precautionary approach, precisely because long-term data is lacking.
At first glance, this appears to be a reasonable conclusion. However, a closer look reveals a more complex picture.
Focusing on the Unknown Instead of What We Do Know
Critics argue that the JRC places too much emphasis on what is not yet known, rather than on the growing body of research that already exists regarding the properties and risk profile of nicotine pouches.
According to Dr Marina Murphy, Senior Director of Scientific Affairs at Haypp:
“It is true that these products are relatively new and that long-term data is still lacking. But that doesn’t mean we are starting from scratch. On the contrary, chemical and toxicological analyses already provide a fairly clear picture.”
One key insight from these studies is that, in terms of composition and exposure, nicotine pouches are far closer to nicotine replacement therapies (NRTs) such as gums and lozenges, than to traditional tobacco products. That distinction is crucial.
No Combustion—And A Fundamentally Different Risk Profile
Cigarettes are harmful primarily because of combustion. When tobacco is burned, it releases a complex mix of toxic and carcinogenic substances.
Nicotine pouches function very differently. They contain no tobacco and involve no combustion. Instead, nicotine is delivered through the oral mucosa – in a way broadly similar to established nicotine replacement therapies.
Products of this kind have been used for decades and are widely regarded as both safe and effective tools for smoking cessation.
It is also important to distinguish nicotine from the primary causes of smoking-related harm. While nicotine is addictive, it is not the main cause of smoking-related diseases. The greatest health risk comes from inhaling smoke – not from nicotine itself.
What Does Real-World Use Show?
Usage patterns also provide important context, something that is often overlooked in policy discussions.
In the United States, where nicotine pouches have gained the most traction, studies show that users are predominantly adults with prior experience of other nicotine products – often current or former smokers.
Similar patterns are observed in the UK, where the majority of users are also current or former smokers or users of other nicotine products.
“This suggests that nicotine pouches are, in practice, largely used as an alternative rather than a gateway into cigarette use,” says Dr Murphy.
A Shift in the Nordics
In the Nordics, developments are moving in the same direction.
Traditional snus, with a history spanning several hundred years, is increasingly being challenged by tobacco-free nicotine pouches. This reflects a broader trend: a shift towards smoke-free alternatives.
A Debate That Risks Becoming One-Dimensional
The JRC report plays an important role in compiling existing evidence and identifying knowledge gaps.
However, when the focus is placed solely on uncertainty, there is a risk that the bigger picture is lost.
For smokers who have not succeeded with traditional quitting methods, nicotine pouches may offer an alternative that is:
- smoke-free
- discreet
- and potentially significantly less harmful
Dr Murphy continues:
“This does not mean the products are risk-free.
There are still important questions to answer, particularly regarding long-term effects and use among young people. But it does mean the discussion needs to weigh both risks and potential.”
From Uncertainty to Harm Reduction
Ultimately, the debate is not only about what we do not yet know – but also about how we use the knowledge we already have.
The JRC itself acknowledges that the evidence remains limited and that further research is needed. At the same time, other studies point to the low levels of harmful exposure associated with nicotine pouches and their similarities to established nicotine replacement therapies.
The key question, therefore, is not only whether uncertainties exist – but how they should be weighed against the opportunity to reduce the harms of smoking today.
